A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma
- Abstract
- In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.
- All Author(s)
- N. J. Cho
; H. S. Lee
; S. H. Jang
; J. S. Choi
; J. O. Na
; K. H. Seo
; Y. H. Kim
; H. C. Kang
; D. Y. Kim
- Issued Date
- 2013
- Type
- Article
- Keyword
- Adenosquamous carcinoma; Epidermal growth factor receptor; Mutation; Non-small-cell lung carcinoma
- Publisher
- Soonchunhyang Medical Research Institute
- ISSN
- 2233-4289
; 2233-4297
- Citation Title
- Soonchunhyang Medical Science
- Citation Volume
- 19
- Citation Number
- 2
- Citation Start Page
- 123
- Citation End Page
- 127
- Language(ISO)
- eng
- DOI
- 10.15746/sms.13.028
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2157
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.